MX2021005144A - Suspension de edaravona para administracion oral. - Google Patents

Suspension de edaravona para administracion oral.

Info

Publication number
MX2021005144A
MX2021005144A MX2021005144A MX2021005144A MX2021005144A MX 2021005144 A MX2021005144 A MX 2021005144A MX 2021005144 A MX2021005144 A MX 2021005144A MX 2021005144 A MX2021005144 A MX 2021005144A MX 2021005144 A MX2021005144 A MX 2021005144A
Authority
MX
Mexico
Prior art keywords
oral administration
edaravone suspension
edaravone
suspension
burden
Prior art date
Application number
MX2021005144A
Other languages
English (en)
Inventor
Kouji Hayashi
Tetsuo Hayama
Tomohiro Takahashi
Tomoyuki Omura
Munetomo Matsuda
Tadashi Miyazawa
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=70463399&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2021005144(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Publication of MX2021005144A publication Critical patent/MX2021005144A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Esta invención provee una suspensión de edaravona para administración oral que tiene excelente biodisponibilidad. Se espera que la carga en los pacientes con ALS y cuidadores pueda reducirse de este modo.
MX2021005144A 2018-11-02 2019-11-01 Suspension de edaravona para administracion oral. MX2021005144A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018207646 2018-11-02
PCT/JP2019/043013 WO2020091036A1 (ja) 2018-11-02 2019-11-01 経口投与用エダラボン懸濁剤

Publications (1)

Publication Number Publication Date
MX2021005144A true MX2021005144A (es) 2021-07-15

Family

ID=70463399

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2021005144A MX2021005144A (es) 2018-11-02 2019-11-01 Suspension de edaravona para administracion oral.
MX2024000663A MX2024000663A (es) 2018-11-02 2021-04-30 Suspension de edaravona para administracion oral.
MX2023009973A MX2023009973A (es) 2018-11-02 2021-04-30 Suspension de edaravona para administracion oral.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2024000663A MX2024000663A (es) 2018-11-02 2021-04-30 Suspension de edaravona para administracion oral.
MX2023009973A MX2023009973A (es) 2018-11-02 2021-04-30 Suspension de edaravona para administracion oral.

Country Status (17)

Country Link
US (5) US10987341B2 (es)
EP (2) EP3875085B1 (es)
JP (2) JP7274502B2 (es)
KR (1) KR20210087490A (es)
CN (4) CN117379369A (es)
AR (1) AR116967A1 (es)
AU (1) AU2019369843A1 (es)
BR (1) BR112021008197A2 (es)
DK (1) DK3875085T3 (es)
FI (1) FI3875085T3 (es)
IL (1) IL282773A (es)
MX (3) MX2021005144A (es)
PH (1) PH12021550988A1 (es)
PT (1) PT3875085T (es)
SG (1) SG11202104365QA (es)
TW (1) TW202031256A (es)
WO (1) WO2020091036A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019167178A1 (ja) * 2018-02-28 2019-09-06 田辺三菱製薬株式会社 ３－メチル－１－フェニル－２－ピラゾリン－５－オン原薬の分析方法、筋萎縮性側索硬化症の治療および筋萎縮性側索硬化症の進行抑制、ならびに、３－メチル－１－フェニル－２－ピラゾリン－５－オン原薬を含む薬剤の製造方法
TW202031256A (zh) * 2018-11-02 2020-09-01 日商田邊三菱製藥股份有限公司 經口投予用依達拉奉(Edaravone)懸浮劑
US11826352B2 (en) * 2018-11-02 2023-11-28 Mitsubishi Tanabe Pharma Corporation Edaravone suspension for oral administration
EP3989968A4 (en) * 2019-07-18 2023-07-12 BDR Pharmaceuticals International Private Limited ORAL FORMULATIONS OF EDARAVON AND PROCESSES FOR THEIR PREPARATION
WO2022102737A1 (ja) 2020-11-12 2022-05-19 田辺三菱製薬株式会社 エダラボン経口投与用医薬組成物およびその投与方法
JPWO2022102737A1 (es) 2020-11-12 2022-05-19
GB202103807D0 (en) 2021-03-18 2021-05-05 Johnson Matthey Plc A crystalline salt of edaravone, processes for the preparation and use thereof
CN118632692A (zh) 2022-02-03 2024-09-10 田边三菱制药株式会社 用于治疗肌萎缩侧索硬化症或抑制肌萎缩侧索硬化症进展的药剂

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61263917A (ja) 1985-05-20 1986-11-21 Mitsubishi Yuka Yakuhin Kk 脳機能正常化剤
JPH07121861B2 (ja) 1986-11-25 1995-12-25 三菱化学株式会社 ３−メチル−１−フエニル−２−ピラゾロン−５−オンを含有する安定な注射剤
JPH0531523A (ja) 1991-07-26 1993-02-09 Aichi Steel Works Ltd ロ−ラ回転数・間隙測定可能な圧延機用ロ−ラガイド装置
JP3402195B2 (ja) * 1997-05-14 2003-04-28 千寿製薬株式会社 再分散性の良い水性懸濁液剤
JPH1120463A (ja) 1997-06-30 1999-01-26 Zexel Corp 車両用デュアルエアコン
US6933310B1 (en) 2000-10-24 2005-08-23 Mitsubishi Pharma Corporation Therapeutic agent for amyotrophic lateral sclerosis (ALS)
JP2004091441A (ja) 2002-09-04 2004-03-25 Mitsubishi Pharma Corp ピラゾロン誘導体を含有する経口投与製剤
JP4988204B2 (ja) 2004-02-09 2012-08-01 田辺三菱製薬株式会社 筋萎縮性側索硬化症（ａｌｓ）又はａｌｓに起因する疾患の新規治療剤
JP5836004B2 (ja) * 2010-08-12 2015-12-24 日新化成株式会社 可溶化剤
US9642843B2 (en) 2013-02-27 2017-05-09 The Regents Of The University Of Michigan Pharmaceutical compounds and use of same in cancer and tauopathies
JP6336246B2 (ja) * 2013-03-13 2018-06-06 大同化成工業株式会社 ナノ粒子化製剤及びその製造方法
TWI745358B (zh) * 2016-03-10 2021-11-11 日商大日本住友製藥股份有限公司 含有細微粒子之組合物及其製法
CN105816423B (zh) * 2016-03-16 2018-07-20 福建天泰医药科技有限公司 依达拉奉剂型
IL268127B1 (en) * 2017-01-17 2024-08-01 Treeway Tw001 B V Preparations containing adrevan for oral or gastric administration and their use for treatment
DK3570819T3 (da) * 2017-01-17 2021-04-06 Treeway Tw001 B V Medicinsk behandling omfattende enteral indgivelse af edaravone
KR20200024868A (ko) * 2017-07-06 2020-03-09 트리웨이 티더블유001 비.브이. 산화성 스트레스-매개 신경퇴행성 질환의 경구 치료에 사용하기 위한 에다라본의 용도
TW202031256A (zh) * 2018-11-02 2020-09-01 日商田邊三菱製藥股份有限公司 經口投予用依達拉奉(Edaravone)懸浮劑
EP3989968A4 (en) * 2019-07-18 2023-07-12 BDR Pharmaceuticals International Private Limited ORAL FORMULATIONS OF EDARAVON AND PROCESSES FOR THEIR PREPARATION

Also Published As

Publication number Publication date
CN117379369A (zh) 2024-01-12
CN117379370A (zh) 2024-01-12
IL282773A (en) 2021-06-30
EP3875085A1 (en) 2021-09-08
EP4420724A2 (en) 2024-08-28
US20210212990A1 (en) 2021-07-15
DK3875085T3 (da) 2024-07-08
US11957660B2 (en) 2024-04-16
US11241416B2 (en) 2022-02-08
TW202031256A (zh) 2020-09-01
EP3875085A4 (en) 2022-07-27
US20240226064A1 (en) 2024-07-11
WO2020091036A1 (ja) 2020-05-07
BR112021008197A2 (pt) 2021-08-03
US20230030285A1 (en) 2023-02-02
CN112969459B (zh) 2023-12-05
JPWO2020091036A1 (ja) 2021-09-24
US11478450B2 (en) 2022-10-25
KR20210087490A (ko) 2021-07-12
AU2019369843A2 (en) 2023-02-02
AR116967A1 (es) 2021-06-30
US20220110915A1 (en) 2022-04-14
JP2023087011A (ja) 2023-06-22
AU2019369843A1 (en) 2021-05-27
PT3875085T (pt) 2024-08-09
MX2024000663A (es) 2024-01-31
US20200268712A1 (en) 2020-08-27
US10987341B2 (en) 2021-04-27
PH12021550988A1 (en) 2021-10-04
JP7274502B2 (ja) 2023-05-16
FI3875085T3 (fi) 2024-08-06
MX2023009973A (es) 2023-09-06
CN112969459A (zh) 2021-06-15
EP3875085B1 (en) 2024-06-19
CN117398346A (zh) 2024-01-16
SG11202104365QA (en) 2021-05-28

Similar Documents

Publication Publication Date Title
PH12021550988A1 (en) Edaravone suspension for oral administration
TWD193695S (zh) 口腔保健用具（三）
TWD208079S (zh) 鼻管組合及其配件
TWD197206S (zh) 口腔保健用具的替換頭部（三）
TWD219405S (zh) 病患連接裝置
TWD200678S (zh) 口腔內攝影機
TWD192740S (zh) 病患連接裝置的頭罩帶
TWD186056S (zh) 藥物注射器（二）
TWD200284S (zh) 口腔保健用具
TWD190209S (zh) 心電圖機
SG10201807070YA (en) Respiratory mask with nasogastric tube path
TWD198853S (zh) 口腔保健用具
TWD196687S (zh) 口腔保健用具（一）
MA40539A (fr) Procédés de formulation de compositions de conjugués anticorps-médicaments
TWD216422S (zh) 醫療用通氣管
TWD196337S (zh) 口腔保健器具（一）
IL273931A (en) Patient care system
TWD192266S (zh) 藥劑輸注裝置之部分
NZ738524A (en) Pharmaceutical formulations comprising rilpivirine hydrochloride, tenofovir alafenamide hemifumarate, and emtricitabine
SG11202108586WA (en) Nursing care device
TWD196171S (zh) 口腔保健用具（一）
TWD196684S (zh) 口腔保健用具的跟蹤模組（一）
PH12016502235A1 (en) Pharmaceutically acceptable salts of pirlindole enantiomers for use in medicine
TWD196683S (zh) 口腔保健用具
MX2020007627A (es) Uso de la carrimicina o de sus ingredientes activos.